



BIODIEM LTD
ABN 20 096 845 993
Level 4,
100 Albert Rd,
South Melbourne, Victoria, 3205
Australia
Phone: +613 9692 7240
Web: www.biodiem.com

Announcement

Griffith Uni's Industry Fund collaborates in BDM-I screening

Melbourne, 29 May 2014: Australian infectious disease therapy and vaccine development company BioDiem Ltd today announced a collaboration with Griffith University's Institute of Glycomics under the Griffith University Industry Collaborative Scheme (GUICS).

This is a co-funded project to

- 1) screen candidate proteins that potentially interact with BDM-I; and thereafter
- 2) explore predicted binding interactions between BDM-I and the candidate proteins.

This work will identify the possible chemical candidates which are structurally related to BDM-I from the protein database bank. This database already contains all currently known structures between protein targets and their ligands. BDM-I will then be verified against the identified targets and the results will feed into a growing information package about how BDM-I works as an antimicrobial. This information could also assist in screening the testing required to support the safety profile of BDM-I in its development.

The work will be co-funded by Griffith University's Industry Fund and BioDiem. This collaborative project will be led by Professor Yaoqi Zhou and Dr. Joe Tiralongo. Professor Zhou is an established world leader in computational screening and structure-based prediction of protein interactions with more than 130 publications. Dr Tiralongo is an internationally recognised glyco biologist, with over 50 publications and extensive experience in analysing small molecule-protein interactions.

ENDS

About Institute of Glycomics

The Institute for Glycomics is the only one of its kind in the southern hemisphere and only one of a few multi-disciplinary glycoscience research centres in the world. Over the past 3 years the Institute for Glycomics has attracted funding and investment in excess of \$30 million for infectious disease and carbohydrate-related research and infrastructure. The Institute for Glycomics has a broad scientific staff profile of approximately 150 researchers that currently consists of eight full Professors and one Associate Professor. In addition to the Professoriate the Institute has several Senior Research Fellows/Senior Lecturers and ARC and NHMRC funded Postdoctoral Fellows. This collaborative project will be led by Professor Yaoqi Zhou and Dr. Joe Tiralongo. Professor Zhou is an established world leader in computational screening and structure-based prediction of protein interactions with more than 130 publications. Dr Tiralongo is an internationally recognised glyco biologist, with over 50 publications and extensive experience in analysing small molecule-protein interactions.

About BioDiem Ltd

BioDiem is an Australian biopharmaceutical company developing vaccines and antimicrobials targeting treatment and prevention of infectious diseases and related cancers. BioDiem's business model is to generate income from partnerships including with other vaccine development companies through existing and new licences to its LAIV vaccine and other technologies. BioDiem's revenue comes from licence fees and royalties on sales.

BioDiem's lead technology is the LAIV (Live Attenuated Influenza Virus) vaccine used for seasonal and pandemic influenza vaccines and is given intranasally. This technology is licenced to the World Health Organisation as part of the Global Pandemic Influenza Action Plan to Increase Vaccine Supply. For additional information, please visit www.biodiem.com.

About BDM-I

BDM-I is a synthetic antimicrobial compound targeting the treatment of serious human infections. BDM-I is active against a range of pathogenic micro-organisms. Key patents have been granted in Europe, Japan and the US around BDM-I's antimicrobial activity. BioDiem has benefited from work conducted by major research institutions in the United States that have undertaken R&D studies of BDM-I. BDM-I is in the preclinical stage of development and BioDiem seeks co-development partners and potential licencees.

Further information

Julie Phillips, Chief Executive Officer
BioDiem Ltd
Phone +61 3 9692 7240
Email jphillips@biodiem.com